The detection result analysis on the immune functions in cirrhosis patients with liver cancer and patients with liver cancer alone

doi:10.3969/j.issn.1673-8640.2014.11.012

Abstract

Abstract:

Objective　To investigate the changes of cellular and humoral immune functions in cirrhosis patients with liver cancer and patients with liver cancer alone. Methods　A total of 40 cirrhosis patients with liver cancer and 40 patients with liver cancer alone were enrolled. At the same period， 40 healthy subjects with no liver disease history were enrolled as controls. Their peripheral blood samples were extracted， and their cellular immune level changes were determined by flow cytometry， including T lymphocyte subset（CD3， CD4， CD8 and CD4 / CD8） values. The concentrations of humoral immunity（IgA， IgG and IgM） were determined by immunoturbidimetry. Results　The CD3， CD4 and CD4/CD8 significantly decreased in liver cancer patients than in controls（P＜0.05）， and the CD3， CD4 and CD4/CD8 in cirrhosis patients with liver cancer decreased obviously compared with those in patients with liver cancer alone（P＜0.05）. Compared with those in controls， the IgA， IgG and IgM increased obviously in liver cancer patients， and the IgA， lgG and lgM increased obviously in cirrhosis patients with liver cancer compared with those in patients with liver cancer alone（P＜0.05）. Conclusions　The immune functions of cirrhosis patients with liver cancer decrease more significantly than those of patients with liver cancer alone. Therefore， improving the immune functions in patients with liver cancer and rebuilding the defense system are so important， and monitoring the changes of immune functions has a positive role for estimating prognosis and guiding clinical treatment.

Key words: Liver cancer, Cirrhosis, Cellular immunity, Humoral immunity

CLC Number:

R446.11

ZHANG Yichao, XIA Jun, LI Xiong. The detection result analysis on the immune functions in cirrhosis patients with liver cancer and patients with liver cancer alone[J]. , 2014, 29(11): 1128-1131.

References

[1] Guglielmi A, Ruzzenente A, Conci S, et al.Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations[J]. World J Gastroenterol, 2014, 20(24):7525-7533.
[2] Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions[J]. Hepatology, 2014. [Epub ahead of print]
[3] 王坤,房萌,赵琳,等. 肝硬化及原发性肝癌患者血清半胱氨酸蛋白酶抑制剂C水平的改变及其意义[J].检验医学, 2012, 27(2):118-121.
[4] Yan J, Liu XL, Xiao G, et al. Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma[J]. PLoS One, 2014, 9(5):e96080.
[5] Hutcheson J, Bourgo RJ, Balaji U, et al. Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma[J]. Hepatology, 2014, 60(4): 1231-1240.
[6] Guo CL, Yang XH, Cheng W, et al. Expression of Fas/FasL in CD8+ T and CD3+ Foxp3+ Treg cells relationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients[J]. Asian Pac J Cancer Prev, 2014,15 (6):2613-2618.
[7] Wu J, Zou H, Jiang JT, et al.Clinical application of serum alpha-fetoprotein-IgM complexes on the diagnosis of primary hepatocellular carcinoma in Kazakh and Han populations[J]. Tumori, 2013, 99(4):535-539.
[8] Arahata M, Tajiri K, Nomoto K, et al. A novel type of selec-tive immunoglobulin m deficiency in a patient with autoimmune liver cirrhosis with recurrent hepatocellular carcinoma: a case report and review of the literature[J]. Int Arch Allergy Immunol, 2013,161(1):91-6.
[9] Ai J, Tang Q, Wu Y, et al. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma[J]. J Natl Cancer Inst, 2011, 103(22):1696-1712.
[10] Wang M, Wang H, Tang Y, et al. Effective inhibition of a Strongylocentrotus nudus eggs polysaccharide against hepatocellular carcinoma is mediated via immunoregulation in vivo[J]. Immunol Lett, 2011, 141(1):74-82.

[1]	GU Yi, WANG Rui, DENG Jie, YANG Yijing, ZHOU Wangke, CHEN Yunuo, CHEN Xiaosong, SHEN Wei, ZHOU Jingyi. Differential analysis and prognostic diagnostic value of inflammatory biomarkers in liver transplantation in patients with severe hepatitis and cirrhosis [J]. Laboratory Medicine, 2023, 38(11): 1044-1051.
[2]	JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609.
[3]	WU Sujun, JI Hengtao, PENG Mengle. Clinical values of IL-18,IL-37,NLRP3 and NK/DC ratio in hepatitis B-related liver cirrhosis [J]. Laboratory Medicine, 2022, 37(6): 518-523.
[4]	LIU Tingting, LIN Yuting, Mila , LI Xiaoqin. Correlation between serum IL-33 level and its gene polymorphism and the clinical outcome of HBV infection [J]. Laboratory Medicine, 2021, 36(11): 1101-1105.
[5]	BIE Lihan, FANG Meng, FENG Huijuan, LU Zhicheng, GAO Chunfang. Role of sialylated haptoglobin for the auxiliary diagnosis of hepatitis B-related hepatocellular carcinoma [J]. Laboratory Medicine, 2020, 35(11): 1147-1152.
[6]	XIAO Xiao, GAO Chunfang. Research and application progress of circulating tumor cells in primary liver cancer [J]. Laboratory Medicine, 2019, 34(7): 661-666.
[7]	LI Jinghua, ZHAO Wei, TONG Jingjing, ZHANG Tie, CAO Yongtong. Risk factors of decompensated liver cirrhosis in primary biliary cirrhosis [J]. Laboratory Medicine, 2018, 33(5): 399-403.
[8]	YE Zhenxuan, YANG Biwei, ZHOU Wenjing, LIU Qiang, LI Hongmei, ZHANG Haiyan, REN Zhijing, ZHANG Hua. Screening of specific anti-mitochondrial antibody-M2 in 36 459 healthy subjects in Guiyang [J]. Laboratory Medicine, 2018, 33(3): 205-208.
[9]	KANG Haiyan, HAO Ruofei, REN Ciju. Relationship between angiotensin Ⅱ level and the severity of liver cirrhosis [J]. Laboratory Medicine, 2018, 33(12): 1112-1115.
[10]	LIANG Dongyu, HOU Yanqiang, LOU Xiaoli. Relationship of DcR3 expression with Fas expression in patients with chronic hepatitis B,liver cirrhosis and liver cancer [J]. Laboratory Medicine, 2017, 32(3): 178-181.
[11]	AN Liyun, WANG Fukun, JIA Keran, LIU Yanli, TANG Fei, WANG Xianling, LI Fang. Influence of military stress on immune function among recruits [J]. Laboratory Medicine, 2016, 31(3): 189-194.
[12]	FU Haitao, YANG Min, HUANG Fenglou, LIANG Yan, ZHONG Renqian. Change of red blood cell distribution width and its significance in patients with primary biliary cirrhosis [J]. Laboratory Medicine, 2015, 30(9): 871-873.
[13]	CAI Yiting, HUANG Sheng, XIE Songye. Analysis on the positive rate of M2 anti-mitochondrial antibodies in physical examine screening in Shanghai [J]. Laboratory Medicine, 2015, 30(3): 214-218.
[14]	LI Feng, WEI Qun, HUANG Dongfeng, ZHANG Hon. Expressions and significance of gp96 and Mcl-1 in liver cirrhosis and hepatocellular carcinoma tissues [J]. Laboratory Medicine, 2015, 30(2): 185-190.
[15]	ZHANG Haiping, YAN Huiping, ZHANG Xin, ZHAO Dantong, MA Yinxue, SUN Limei, LI Zhuomin.. Automatic ELISA system for the detection of anti-mitochondrial M2 antibody and its clinical significance [J]. Laboratory Medicine, 2015, 30(12): 1234-1237.